Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Mullally

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Cell Stem Cell|May 2, 2017
Gli1<sup>+</sup> Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic TargetRebekka K Schneider, Ann Mullally, Aurelien Dugourd, et al.
Nature|July 24, 2012
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapyPriya Koppikar, Neha Bhagwat, Outi Kilpivaara, et al.
Leukemia|November 17, 2019
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populationsRebecca J Austin, Jasmin Straube, Claudia Bruedigam, et al.
Cell Stem Cell|February 23, 2021
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative NeoplasmsDebra Van Egeren, Javier Escabi, Maximilian Nguyen, et al.
Leukemia|February 26, 2026
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicingJonas S Jutzi, Edie Crosse, Chulwoo J Kim, et al.
Cancer Cell|September 14, 2016
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome ModulationEsther A Obeng, Ryan J Chappell, Michael Seiler, et al.
Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.
Science Translational Medicine|April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasmsOfir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Leukemia|February 24, 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasmsBenjamin Rolles, Cilomar Martins de Oliveira Filho, Nathan Fergusson, et al.
Nature|November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasmsAshok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Cell Stem Cell|May 2, 2017
Gli1<sup>+</sup> Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic TargetRebekka K Schneider, Ann Mullally, Aurelien Dugourd, et al.
Nature|July 24, 2012
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapyPriya Koppikar, Neha Bhagwat, Outi Kilpivaara, et al.
Leukemia|November 17, 2019
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populationsRebecca J Austin, Jasmin Straube, Claudia Bruedigam, et al.
Cell Stem Cell|February 23, 2021
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative NeoplasmsDebra Van Egeren, Javier Escabi, Maximilian Nguyen, et al.
Leukemia|February 26, 2026
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicingJonas S Jutzi, Edie Crosse, Chulwoo J Kim, et al.
Cancer Cell|September 14, 2016
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome ModulationEsther A Obeng, Ryan J Chappell, Michael Seiler, et al.
Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.
Science Translational Medicine|April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasmsOfir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Leukemia|February 24, 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasmsBenjamin Rolles, Cilomar Martins de Oliveira Filho, Nathan Fergusson, et al.
Nature|November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasmsAshok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Pageof 7